Clinical Trial Update: 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF [Phase 3]

View source ↗

Summary

Phase 3 trial comparing an epirubicin/cyclophosphamide regimen followed by docetaxel versus six-cycle CMF/CEF in breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CEF (cyclophosphamide, epirubicin, and fluorouracil)
• CMF (cyclophosphamide, methotrexate, and fluorouracil)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED